Key clinical point: The 1-year nonrelapse mortality and overall survival were 1.7% and 69%, respectively.
Major finding: A total of 539 grade 2 or greater and 280 grade 3 or greater toxicities were observed.
Study details: Toxicities in organ-based groups assessed in 60 patients with DLBCL treated with CD19 CAR T cells.
Disclosures: The authors reported various relationships with multiple pharmaceutical and biotechnology companies.
Wudhikarn K et al. Blood Advances. 2020; 4:3024-33.